OOIR: Observatory of International Research

Papers

(The TQCC of Blood Cancer Journal is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort	159
Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma	159
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M	143
Disparities in time to treatment with oral antimyeloma medications	138
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib	121
Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity	115
Correction: Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells	112
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT	105
Common cardiovascular biomarkers can independently predict outcome of patients with Myelodysplastic syndromes	102
In response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study	99
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine	98
Genomic landscape of hyperleukocytic acute myeloid leukemia	95
Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma	88
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma	81
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes	80
Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease	79
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients	74
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency	72
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid	71
Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study	69
Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia	68
Dynamics of microcyst-like epithelial changes associated with Belantamab mafodotin therapy in a patient with multiple myeloma—a case report	68
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma	67
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management	65
Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm	63

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor	59
A multiparametric niche-like drug screening platform in acute myeloid leukemia	58
Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study	57
T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma	53
Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia	50
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression	49
Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study	48
Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis	47
CALRins5-mediated clonal hematopoiesis causes severe hemolytic anemia in a female PGK1Ser320Asn carrier	46
Should I stay or should I go (to transplant)? Managing insufficient responses to induction in multiple myeloma	45
Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma	44
RSK1 dependency in FLT3-ITD acute myeloid leukemia	44
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma	44
Genome profiling with targeted adaptive sampling long-read sequencing for pediatric leukemia	43
Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome	43
Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment	42
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review	42
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial	41
Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies	40
Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review	39
The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy	38
Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma	37
Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity	37
Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors	37
Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world data	37
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial	36
Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma	36
Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia	35
Characteristics and predictors of central nervous system relapse in newly diagnosed acute promyelocytic leukemia in the era of arsenic: a 13-year monocenter cohort study	35
Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma	35
Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma	34
Bispecific antibodies in the treatment of multiple myeloma	34
Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis	34
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia	32
Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations	32
Prognostic and therapeutic implications of TP53 expression in chronic myelomonocytic leukemia	31
Extended DaraKRd: Are we enhancing outcomes by prolonging treatment?	31
Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort study	31
Management of chronic myeloid leukemia in 2023 – common ground and common sense	31
Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models	31
Clinical characteristics and outcomes of 476 mantle cell lymphoma patients aged 80 years and older	31
Deep immune cell profiling in blood and bone marrow of early stage monoclonal gammopathy: an iStopMM and ECRIN-M3 collaborative study	30
Author Correction: Germline variants at SOHLH2 influence multiple myeloma risk	30
Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999	30
Improving outcomes with anti-BCMA bispecific antibodies with attention to infection	29
Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection	29
Risk of lymphoid malignancy associated with cancer predisposition genes	29
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial	29
Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years	28
Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases	28

The long shadow of socioeconomic deprivation over the modern management of acute myeloid leukemia: time to unravel the challenges	28
Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians	28
Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial	27
Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials	27
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)	27
CD19-targeted BiTE expression by an oncolytic vaccinia virus significantly augments therapeutic efficacy against B-cell lymphoma	27
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage	27
Smoldering multiple myeloma current treatment algorithms	27
Coincidence of cutaneous blastic plasmacytoid dendritic cell neoplasm and myelodysplastic syndrome derived from clonal hematopoiesis	26
Drug development in higher-risk myelodysplastic syndromes	26
Correction: TET2 deficiency promotes MDS-associated leukemogenesis	26
Fertility and parenthood in patients with acute promyelocytic leukemia treated with Arsenic Trioxide and All-Trans retinoic acid	26
Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2V617F myeloproliferative neoplasms	25
Donor cell-derived genetic abnormalities after sex mismatched allogeneic cell transplantation: a unique challenge of donor cell leukemia	25
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial	25
Age-stratified analysis reveals arterial thrombosis as a predictor for gender-related second cancers in myeloproliferative neoplasms: a case-control study	24
Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients	24
Primary cells from patients with adult T cell leukemia/lymphoma depend on HTLV-1 Tax expression for NF-κB activation and survival	24
A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma	24
Targeting lysine demethylase 5 (KDM5) in mantle cell lymphoma	24
MYC-rearranged mature B-cell lymphomas in children and young adults are molecularly Burkitt Lymphoma	24
Disease characteristics and monitoring of IDH1/IDH2-mutated acute myeloid leukemia	23
Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation	23
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial	23
Reducing the risks of nuclear war—the role of health professionals	23
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk	23
Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019	22
Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect® MM Registry	22
Targeting S100A9 protein affects mTOR-ER stress signaling and increases venetoclax sensitivity in Acute Myeloid Leukemia	22
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma	22
Late effects in survivors of infant acute lymphoblastic leukaemia—a study of the Australian and New Zealand Children’s Haematology/Oncology Group	22
Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy	22
Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms	22
Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients	22
Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma	21
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched study	21
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes	21
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment	20
Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota	20
Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms	20
JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation	20
Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recomm	20
Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms	20
Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities	20
Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapy	20
Haploidentical vs matched sibling donor transplant for paroxysmal nocturnal haemoglobinuria: A multicenter study	20
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation	19
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?	19
Breakthrough infections in MPN-COVID vaccinated patients	19
Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century	19
Cutaneous manifestations of monoclonal gammopathy	19
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages	19
Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry	19
Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab	18
Clonal dynamics of aggressive systemic mastocytosis on avapritinib therapy	18
Genomic profiles and outcomes in de novo versus therapy-related core binding factor AML	18
Mixed T cell lineage chimerism in acute leukemia/MDS using pre-emptive donor lymphocyte infusion strategy—Is it prognostic?—a single-center retrospective study	18
Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation	18
The risk of coronavirus disease 2019 (COVID-19) among individuals with monoclonal B cell lymphocytosis	17
Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies	17
Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression	17
Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma	17
Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis	17
MYC break-apart FISH probe set reveals frequent unbalanced patterns of uncertain significance when evaluating aggressive B-cell lymphoma	17
Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial	16
Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib	16
Survival trends in hematological malignancies in the Nordic countries through 50 years	16
Correction: Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib study	16
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera	16
To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemia	16
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in t	16
TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms	16
The constitutive activation of STAT3 gene and its mutations are at the crossroad between LGL leukemia and autoimmune disorders	16
Drug importation: limitations of current proposals and opportunities for improvement	16
Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement	16
Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies	16
Mendelian randomization of immune cell phenotypes to discover potential drug targets for B-cell malignancy	16
Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party	16
Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience	16
Transformation and outcome of nodular lymphocyte predominant Hodgkin lymphoma: a Finnish Nationwide population-based study	15

Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis	15
Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison	15
Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms	15
Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia	15
Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study	15
Transposable elements as genome regulators in normal and malignant haematopoiesis	15
CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases	15
Identification of NOTCH-driven matrisome-associated genes as prognostic indicators of multiple myeloma patient survival	15
Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study	15
Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study	14
Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation	14
Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm	14
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)	14
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study	14
Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies	14
Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia	14
Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era	14
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements	14
Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group	14
Patient preferences for intervention in the setting of precursor multiple myeloma	13
The expanding CML treatment landscape: an introspective commentary	13
Conditional survival in multiple myeloma and impact of prognostic factors over time	13
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma	13
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee	13
R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma	13
The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia	13
Resistance to targeted therapies: delving into FLT3 and IDH	13
UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome	13
The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma	13
DDX41 germline variants causing donor cell leukemia indicate a need for further genetic workup in the context of hematopoietic stem cell transplantation	13
SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma	13
An atlas of the bone marrow bone proteome in patients with dysproteinemias	13
Patient-specific computational models predict prognosis in B cell lymphoma by quantifying pro-proliferative and anti-apoptotic signatures from genetic sequencing data	13
Immunophenotypic assessment of clonal plasma cells and B-cells in bone marrow and blood in the diagnostic classification of early stage monoclonal gammopathies: an iSTOPMM study	13
I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients	13
Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target	12
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel	12
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse	12
Identification of the estrogen receptor beta as a possible new tamoxifen-sensitive target in diffuse large B-cell lymphoma	12
Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study	12
Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL	12
Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort study	12
Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study	12
Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission	12
Eltrombopag with or without Tacrolimus for relapsed/refractory acquired aplastic anaemia: a prospective randomized trial	12
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study	12
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group	12
A simplified, two-factor clinical prognostic scoring system for patients with newly diagnosed Hodgkins Lymphoma	12
Extramedullary disease in multiple myeloma	12
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy	12
Mode of progression in smoldering multiple myeloma: a study of 406 patients	12
Utility of flow cytometry screening before MRD testing in multiple myeloma	12
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study	12
Racial differences as predictors of outcomes in young patients with multiple myeloma	12